The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)

Author:

Albala Bruce1,Appelmans Eline2,Burress Ramona3,De Santi Susan14,Devins Theresa1,Klein Gregory5,Logovinsky Veronika1,Novak Gerald P.3,Ribeiro Kim6,Schmidt Mark E.7,Schwarz Adam J.8,Scott David9,Shcherbinin Sergey10,Siemers Eric11,Travaglia Alessio2,Weber Christopher J.12,White Leah2,Wolf‐Rodda Julie2,Vasanthakumar Aparna6

Affiliation:

1. Eisai Inc. Nutley New Jersey USA

2. Foundation for the National Institutes of Health North Bethesda Maryland USA

3. Janssen Research & Development, LLC Titusville New Jersey USA

4. Life Molecular Imaging Berlin Germany

5. F. Hoffmann‐La Roche Ltd Basel Switzerland

6. AbbVie Inc. North Chicago Illinois USA

7. Janssen Research & Development Beerse Belgium

8. Takeda Pharmaceutical Company Ltd. Cambridge Massachusetts USA

9. Clario San Mateo California USA

10. Eli Lilly and Company Indianapolis Indiana USA

11. Cogstate Ltd New Haven Connecticut USA

12. Alzheimer's Association Chicago Illinois USA

Abstract

AbstractThe Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) encompasses members from industry, biotechnology, diagnostic, and non‐profit organizations that have until recently been managed by the Foundation for the National Institutes of Health (FNIH) and provided financial and scientific support to ADNI programs. In this article, we review some of the major activities undertaken by the PPSB, focusing on those supporting the most recently completed National Institute on Aging grant, ADNI3, and the impact it has had on streamlining biomarker discovery and validation in Alzheimer's disease. We also provide a perspective on the gaps that may be filled with future PPSB activities as part of ADNI4 and beyond.Highlights The Private Partners Scientific board (PPSB) continues to play a key role in enabling several Alzheimer's Disease Neuroimaging Initiative (ADNI) activities. PPSB working groups have led landscape assessments to provide valuable feedback on new technologies, platforms, and methods that may be taken up by ADNI in current or future iterations.

Funder

Alzheimer's Disease Neuroimaging Initiative

National Institutes of Health

U.S. Department of Defense

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Reference52 articles.

1. Alzheimer's Disease Neuroimaging Initiative.About Alzheimer's disease neuroimaging initiative (ADNI). Accessed on 2017.https://AdniLoniUscEdu/about/#gov‐Containern.d

2. Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)

3. The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board

4. The Montreal Cognitive Assessment: Validity and Utility in a Memory Clinic Setting

5. Rey auditory verbal learning test. encycl;Bean J;Clin Neuropsychol,2011

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3